Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Aclaris Therapeutics revenue
Aclaris Therapeutics's revenue is $18.7 million.
What is Aclaris Therapeutics's revenue?
- Aclaris Therapeutics's revenue growth from 2017 to 2024 is 1,012.3%.
- Aclaris Therapeutics has 60 employees, and the revenue per employee ratio is $312,000.
- Aclaris Therapeutics's peak quarterly revenue was $19.0M in 2022(q3).
- Aclaris Therapeutics peak revenue was $31.2M in 2023.
- Aclaris Therapeutics annual revenue for 2023 was 31.2M, 5.03% growth from 2022.
- Aclaris Therapeutics annual revenue for 2024 was 18.7M, -40.09% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Aclaris Therapeutics historical revenue
Aclaris Therapeutics's peak revenue was $31.2M in 2023. The peak quarterly revenue was $19.0M in 2022(q3).
Aclaris Therapeutics's revenue increased from $1.7m in 2017 to $18.7M currently. That's a 1,012.3% change in annual revenue.
Aclaris Therapeutics annual revenue
Aclaris Therapeutics annual revenue over time
| Fiscal year / year | Aclaris Therapeutics revenue |
|---|---|
| 2017 | $1.7M |
| 2018 | $6.2M |
| 2019 | $4.2M |
| 2020 | $6.5M |
| 2021 | $6.8M |
| 2022 | $29.8M |
| 2023 | $31.2M |
| 2024 | $18.7M |
How accurately did Aclaris Therapeutics' revenue projections match actual performance?
Aclaris Therapeutics annual growth
Aclaris Therapeutics saw the greatest revenue growth in 2022, when revenue increased by 340.05%.
Aclaris Therapeutics had the lowest revenue growth in 2019, when revenue changed by -31.28%.
Aclaris Therapeutics annual growth rate over time
| Year | Aclaris Therapeutics growth |
|---|---|
| 2018 | 265%↑ |
| 2019 | -31%↓ |
| 2020 | 53%↑ |
| 2021 | 4%↑ |
| 2022 | 340%↑ |
| 2023 | 5%↑ |
| 2024 | -40%↓ |
Aclaris Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Aclaris Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2017 | - | - | $684,000 | $999,000 |
| 2018 | $1.1M | $3.7M | $1.1M | $1.8M |
| 2019 | $1.3M | $886,000 | $983,000 | $1.1M |
| 2020 | $1.4M | $2.0M | $1.4M | $1.6M |
| 2021 | $1.8M | $1.8M | $1.7M | $1.5M |
| 2022 | $1.5M | $1.5M | $19.0M | $7.8M |
| 2023 | $2.5M | $1.9M | $9.3M | $17.6M |
| 2024 | $2.4M | $2.8M | $4.3M | $9.2M |
Aclaris Therapeutics jobs nearby
Do you work at Aclaris Therapeutics?
Is Aclaris Therapeutics transparent about its revenue structure?
Aclaris Therapeutics financial information
| CEO | Neal S. Walker |
| Company Type | Public |
| Employees Number | 60 |
| Date Founded | 2012 |
| Headquarters | Malvern, Pennsylvania |
| Number of Locations | 3 |
| Revenue | $18.7M |
| Net Income | -$86,908,000 |
| Gross Proft | $15.9M (2024) |
| Tax Rate | 0.0% |
| Total Assets | $254,596,000 |
| Ticker | ACRS |
Aclaris Therapeutics jobs you might like
Aclaris Therapeutics financing
Aclaris Therapeutics received early financing of $21.0M on 2012-10-24.
| Series | Round size | Date |
|---|---|---|
| Series A | $21M | 10/2012 |
| Series B | $21M | 10/2014 |
| Series C | $40M | 09/2015 |
| Post Ipo Equity | $20M | 06/2016 |
| Post Ipo Equity | $106.9M | 10/2018 |
| Post Ipo Debt | $11M | 03/2020 |
Aclaris Therapeutics investors
| Investors | Security type |
|---|---|
| Vivo Capital | Series A |
| SOFINNOVA INVESTMENTS INC | Series A |
| F Prime Capital | Series A |
| Vivo Capital | Series B |
| SOFINNOVA INVESTMENTS INC | Series B |
| F Prime Capital | Series B |
| Mossrock Capital | Series C |
| Vivo Capital | Series C |
| Cormorant Asset Management | Series C |
| SOFINNOVA INVESTMENTS INC | Series C |
| Aperture Venture Partners | Series C |
| F Prime Capital | Series C |
| RA Capital Management | Series C |
| Rock Springs Capital | Series C |
| Aisling Capital | Post Ipo Equity |
| Silicon Valley Bank | Post Ipo Debt |
Aclaris Therapeutics competitors
Aclaris Therapeutics's top competitor, Axsome Therapeutics, earned an annual revenue of $385.7M.
Aclaris Therapeutics's smallest competitor is GT Biopharma with revenue of $27.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seelos Therapeutics | - | $375,000 | 10 | - |
| Cara Therapeutics | - | $7.1M | 84 | - |
| Turning Point Therapeutics | - | $25.0M | 142 | - |
| Axsome Therapeutics | - | $385.7M | 29 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Centrexion Therapeutics | - | $790,000 | 29 | - |
| Dermira | - | $79.2M | 333 | - |
| Genprex | - | $45.0M | 7 | - |
| Eidos Therapeutics | - | $26.7M | 20 | - |
| GT Biopharma | - | $27,000 | 2 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Aclaris Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Aclaris Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Aclaris Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Aclaris Therapeutics. The data presented on this page does not represent the view of Aclaris Therapeutics and its employees or that of Zippia.
Aclaris Therapeutics may also be known as or be related to ACLARIS THERAPEUTICS INC., Aclaris Therapeutics, Aclaris Therapeutics Inc, Aclaris Therapeutics Inc. and Aclaris Therapeutics, Inc.